• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Myriad Genetics Inc.

    4/25/24 4:18:40 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email
    SC 13G 1 MYGN_SC13G_April2024.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    MYRIAD GENETICS, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.01 PER SHARE
    (Title of Class of Securities)

    62855J104
    (CUSIP Number)

    APRIL 17, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    62855J104

    SCHEDULE 13G

    Page  
    2
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     4,493,261 (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     4,493,261 (See Item 4(a))
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     4,493,261 (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.97%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    62855J104

    SCHEDULE 13G

    Page  
    3
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     4,493,261 (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     4,493,261 (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     4,493,261 (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.97%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    62855J104

    SCHEDULE 13G

    Page  
    4
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     4,493,261 (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     4,493,261 (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     4,493,261 (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.97%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    62855J104

    SCHEDULE 13G

    Page  
    5
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     4,493,261 (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     4,493,261 (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     4,493,261 (See Item 4(a))
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.97%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    62855J104

     SCHEDULE 13G

    Page  
    6
      of   
    11
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Myriad Genetics, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    322 North 2200 West
    Salt Lake City, Utah 84116

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.01 per share ("Common Stock")
     
      (e) CUSIP Number:
    62855J104
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    62855J104

     SCHEDULE 13G

    Page  
    7
      of   
    11
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

       After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on April 17, 2024, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    62855J104

     SCHEDULE 13G

    Page  
    8
      of   
    11

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    62855J104

    SCHEDULE 13G

    Page  
    9
      of   
    11

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of April 24, 2024, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    62855J104

    SCHEDULE 13G

    Page  
    10
      of   
    11
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: April 24, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    62855J104

    SCHEDULE 13G

    Page  
    11
      of   
    11
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.01 per share, of Myriad Genetics, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: April 24, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $MYGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/21/2025$6.00Sector Outperform → Sector Perform
    Scotiabank
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $MYGN
    SEC Filings

    View All

    SEC Form S-3 filed by Myriad Genetics Inc.

    S-3 - MYRIAD GENETICS INC (0000899923) (Filer)

    2/24/26 4:10:08 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by Myriad Genetics Inc.

    10-K - MYRIAD GENETICS INC (0000899923) (Filer)

    2/24/26 4:01:58 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MYRIAD GENETICS INC (0000899923) (Filer)

    2/23/26 4:07:33 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myriad Commercially Launches Precise MRD with Select Community Oncologists

    SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. "The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low levels, the Precise MRD test will enable earlier insight and more informed treatment decisions," said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. "This launch demonstrates the new Myriad's ability

    3/2/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests

    SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular Residual Disease) Test, Prolaris® Prostate Cancer Prognostic Test and MyRisk® Hereditary Cancer Tests. These data highlight Myriad's expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification, and inherited cancer risk assessment. "The data Myriad is presenting at ASCO-GU suggest our oncology products go further than standard approaches to deliver unique insights for p

    2/24/26 9:00:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    $MYGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Myriad Genetics downgraded by Scotiabank with a new price target

    Scotiabank downgraded Myriad Genetics from Sector Outperform to Sector Perform and set a new price target of $6.00

    5/21/25 8:40:26 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics downgraded by Wolfe Research

    Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

    5/8/25 8:27:12 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

    5/7/25 8:36:31 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Officer Solaiman Shereen covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 2% to 109,288 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    3/2/26 4:18:28 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Operating Officer Verratti Mark was granted 32,810 shares, increasing direct ownership by 9% to 414,636 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/3/26 5:30:09 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    2/27/26 4:46:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Leadership Updates

    Live Leadership Updates

    View All

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

    SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scott Leffler, who has served as Chief Financial Officer since January 2024, will transition to a consulting role serving the CEO and the Board of D

    8/18/25 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

    SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. "Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric

    4/7/25 8:00:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Financials

    Live finance-specific insights

    View All

    Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

    Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin was 70.0% and in-line with third quarter 2025. Fourth quarter 2025 GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and ad

    2/23/26 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2025. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please reg

    2/16/26 4:15:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

    SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference. Select Preliminary Four

    1/12/26 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

    SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

    11/14/24 4:16:31 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Myriad Genetics Inc.

    SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    5/1/24 4:21:33 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Myriad Genetics Inc.

    SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    4/25/24 4:18:40 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care